P eripheral arterial disease (PAD) is an increasingly prevalent and costly disease affecting 8-12 million Americans. It is a slowly progressive manifestation of atherosclerotic disease and is particularly prevalent among those 65 years and older (12-15 %; estimated to be 20 % in those over 70), Black Americans (8 %, compared to 4 % in White Americans), and diabetics (approximately 20 % of symptomatic PAD patients). [1] [2] [3] [4] [5] Patients with lower extremity PAD are three to six times more likely to die of cardiovascular disease than those without PAD, and they carry a risk of cardiovascular events as high as that of patients with coronary heart disease, including myocardial infarction. [6] [7] [8] Hypertension is among the strongest and most modifiable risk factors for PAD, yet little is known about the relative efficacy of antihypertensive treatments for lowering PAD Electronic supplementary material The online version of this article (doi:10.1007/s11606-014-2947-1) contains supplementary material, which is available to authorized users.
Published online July 8, 2014 risk. [9] [10] [11] While major studies with potential to impact clinical practice have compared the efficacy of antihypertensive regimens in reducing risk of such major cardiovascular disease events as stroke, myocardial infarction, and heart failure, [12] [13] [14] few active-comparator trials have compared the efficacy of specific antihypertensive drugs in reducing risk of PAD or risk of cardiovascular disease in people with PAD. 15 The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind, activecontrolled trial of 42,418 high-risk hypertensive patients, provides an opportunity to analyze the relative efficacy of antihypertensive drugs in preventing lower extremity PAD hospitalization and outpatient surgical treatment events. ALLHAT also affords the opportunity to evaluate long-term clinical outcomes after PAD hospitalization or revascularization. We previously reported a trend toward reduced risk of PAD events (treated as out-patient or hospitalized; with or without vascularization procedures) in the calcium-channel antagonist amlodipine group (RR, 0.87; 95 % CI, 0.75-1.01; P=0.06), but no difference in the ACE-inhibitor lisinopril group (RR, 1.04; 95 % CI, 0.90-1.19; P=0.63) compared with the diuretic chlorthalidone. 16 Here we use stricter criteria to analyze first in-trial PAD: we look at events that were centrally verified through review of hospital or operative reports and, in addition, look at morbidity and mortality following those events. Aims of this study are to: (1) describe characteristics of patients who developed clinically advanced PAD, i.e., requiring hospitalization or revascularization, by treatment group; (2) compare first occurrence of clinically advanced PAD during ALLHAT by treatment group; (3) compare in-trial morbidity following PAD events by treatment group; (4) compare mortality (cardiovascular, non-cardiovascular, and all-cause) in patients with PAD by treatment group. 17 
METHODS

Design and In-Trial Follow-Up
ALLHAT was designed to determine whether occurrence of fatal coronary heart disease or non-fatal myocardial infarction (primary outcome) is lower for hypertensive patients (BP of 140-180/90-110 for untreated or ≤160/100 for treated patients), age ≥55, assigned to an angiotensinconverting enzyme inhibitor (ACEI; lisinopril), a calcium channel-blocker (CCB; amlodipine), or an alpha-receptorblocker (doxazosin) compared with assignment to treatment with a thiazide-type diuretic (chlorthalidone), who had at least one additional cardiovascular disease risk factor, only one of which was required to be entered on the screening form (even if more were present). Risk factors included old myocardial infarction or stroke, history of coronary revascularization procedure, other documented atherosclerotic cardiovascular disease (category contains PAD, including history of intermittent claudication, peripheral artery revascularization, or peripheral artery angioplasty/stent), type 2 diabetes, current cigarette smoking, HDL<0.90 mmol/l, left ventricular hypertrophy, major ST depression, or T-wave inversion. History of PAD was not otherwise collected at baseline. Randomized treatment assignments were allocated in a 1.7:1:1:1 ratio to chlorthalidone, amlodipine, lisinopril, and doxazosin, respectively. Participants (n=42,418) were recruited between February 1994 and January 1998. All participants gave written informed consent, and all centers obtained institutional review board approval. The JNC-5 provided blood pressure (BP) guidelines for ALLHAT. 18 Each of the masked, randomly assigned (step 1) study drugs had three dosage levels. If participants failed to meet the BP goal at the maximum tolerated dose, second-(step 2) and third-line (step 3) drugs were available to be added to the blinded study drug at the site investigator's discretion: step 2, atenolol, 25-100 mg/day; reserpine, 0.05-0.2 mg/day; and clonidine 0.1-0.3 mg/day, titrated in three doses, and step 3, hydralazine, 25-100 mg twice/day. Low doses of open-label step 1 classes were permitted if clear medical indications developed. Site coordinators were trained and regularly tested in BP measurement; participants' BPs were measured at 3-4-month follow-up visits using standard mercury sphygmomanometers. 19 The doxazosin arm was stopped early because of futility and increased cardiovascular disease, especially heart failure, in the doxazosin arm compared with the chlorthalidone arm. 20 Results of the other two treatment group comparisons were published in 2002. 16 Mean in-trial follow-up for amlodipine and lisinopril versus chlorthalidone comparisons was 4.9 years (3.2 years in the doxazosin comparison with chlorthalidone). Due to differential follow-up times of participants assigned to the alpha-1 antagonist doxazosin treatment group, the doxazosin-chlorthalidone comparison was not included in current analyses, and the remainder of this report reflects experiences for the 33,357 participants in the chlorthalidone, amlodipine, and lisinopril arms.
PAD, a component of a major secondary outcome, is defined in the ALLHAT protocol as: (1) hospitalized, with or without a revascularization procedure (lower extremity angioplasty, stent, or bypass surgery documented by hospital discharge summary, procedure sheet, or face sheet); or (2) outpatient revascularization procedure (documented by procedure sheet); or, (3) treated medically, as per the attending physician's usual care regimen, as an outpatient (documented by check box on endpoint questionnaire). 21 Hospitalizations and revascularizations were reported by clinical site investigators to the Coordinating Center, where a physician-led endpoints group centrally reviewed all reports and corresponding documentation, including discharge summaries for hospitalizations and operative reports for non-hospitalized revascularization procedures. Pre-specified subgroups included: (1) men vs. women, (2) participants <65 vs. ≥65 years, (3) Black vs. non-Black participants, and (4) diabetic vs. non-diabetic participants.
Post-hoc subgroups included presence or absence of coronary heart disease at baseline. In the main results publication, PAD was reported as per the protocolspecified definition. 16 For PAD events reported in this article, we restricted analyses to verifiable lower extremity arterial disease events, i.e., documented hospitalizations and revascularization procedures that occurred during the randomized phase of ALLHAT. We further limited review to participants for whom post-trial mortality data were available. 17 Hereafter, PAD events will refer to the first post-randomization clinically advanced PAD event, i.e., hospitalization or revascularization procedure.
Post-Trial Follow-Up
Detailed descriptions of post-trial follow-up aims and procedures as well as main results of the extended follow-up through 2006 for the amlodipine and lisinopril comparisons with chlorthalidone have been published. 17 Briefly, following the in-trial phase, and per prior Institutional Review Board permission, we conducted an extended follow-up of ALLHAT participants through national administrative databases for an average of 4 years, providing an overall average follow-up time of 8.8 years (4.9 years during active trial treatment and 3.9 years following trial cessation). Post-trial deaths following first in-trial PAD events were ascertained using administrative databases, as described below. Post-trial morbidity (non-fatal hospitalization) data were not available for the 5,558 Veterans' Affairs (VA) participants in ALLHAT, including 281 VA participants with in-trial PAD; therefore, post-PAD non-fatal events are described only through the end of the active trial. In addition, database access was not available for Canadian participants including the eight Canadian participants with in-trial PAD. Finally, post-trial data on medications, BP, outpatient morbidity and treatment, and laboratory data were not collected via administrative databases. 17 
Mortality Outcomes
During the in-trial phase, cause of death was determined by investigators. Mortality data were available through national administrative databases for the entire cohort during both in-trial and post-trial periods, except for participants enrolled in Canada, as noted above. Both the National Death Index (NDI) and Social Security Administration databases were used to collect all-cause mortality. Death certificates were obtained for those deaths discovered through the administrative databases and used to confirm patient identification; the NDIPlus provided ICD-10 codes with causes of death. Additional details of the mortality outcome have been published. 17 
Statistical Methods
Data were analyzed according to each participant's randomized treatment assignments (intent-to-treat analysis). Baseline characteristics and intermediate outcomes were compared across three treatment groups using the Z-test for continuous covariates and contingency table analysis for categorical data. Cumulative event rates were calculated using the Kaplan-Meier method. Hazard ratios and 95 % confidence intervals (CIs) were obtained from the Cox proportional hazards regression model. 22 The follow-up period includes both randomized trial (mean follow-up duration 4.9 years) and subsequent extension period followup (3.9 years). The proportional hazards regression model incorporated the participant's entire trial experience to evaluate differences between cumulative event curves and to obtain two-sided P values. Heterogeneity of effects in subgroups was examined by testing for treatment-covariate interaction with the Cox proportional hazards regression model, using P<0.05. Multivariate Cox regression models were employed to examine differences in risk across randomized treatment comparisons, unadjusted and while controlling for age, race, ethnicity, gender, previous treatment for hypertension, pulse pressure, heart rate, current or former smoking, type II diabetes, evidence of coronary heart disease, aspirin use, history of CABG, history of myocardial infarction or stroke, and body mass index (BMI). A P-value <0.05 was used to indicate statistical significance for results. Post-PAD mortality rates were calculated using the Kaplan-Meier method. However, given the many main, subgroup, and interaction analyses performed, statistical significance at the 0.05 level should be interpreted cautiously.
RESULTS
Of 32,804 participants eligible for long-term mortality follow-up (33,357, less 553 Canadian participants), 830 (2.5 %) participants experienced clinically severe PAD (i.e., requiring hospitalizations or outpatient revascularization procedures) during the active follow-up phase of ALLHAT: 402, or 2.7 % of the chlorthalidone group, 198, or 2.2 % of the amlodipine group, and 230, or 2.6 % of the lisinopril group. Mean time to detection of PAD was 2.6 years for the chlorthalidone and lisinopril groups and 2.8 years for the amlodipine group. Among the 830 participants, 520 (63 %) died: 64.2 % in the chlorthalidone group, 60.1 % in the amlodipine group, and 62.2 % in the lisinopril group. Nearly half (241, 46 %) of the 520 deaths occurred in-trial while 279 (54 %) occurred post-trial (Fig. 1) .
History of PAD at entry into ALLHAT was not directly ascertained. Baseline characteristics by assigned treatment group of those who experienced clinically severe PAD during the study are presented in Table 1 . Those on chlorthalidone were more likely to have type 2 diabetes than those on lisinopril (P=0.011) and less likely to take aspirin than those on amlodipine (P=0.029). The chlorthalidone group had a lower total (P=0.004) and borderline lower LDL-cholesterol (P= 0.051) than the amlodipine group and a lower total cholesterol than the lisinopril group (P=0.033). Compared with those assigned to amlodipine and lisinopril, those on chlorthalidone tended to be slightly older, to have higher mean fasting glucose levels, were less likely to be female, and were less likely to have other major cardiovascular disease. Percent of PAD patients who had ever smoked was slightly lower in the amlodipine group compared to the chlorthalidone and lisinopril groups (76.3, 78.3, and 78.3 %, respectively). There was no difference in either the amlodipine vs. chlorthalidone or lisinopril vs. chlorthalidone comparisons in current (P=0.234 and P=0.986, respectively) or former (P=0.977 and P=0.974, respectively) smokers compared to those never having smoked.
In-trial medication status and mean BPs by randomized treatment group for those with and without in-trial PAD events are shown in the online appendix. Kaplan-Meier plots and Cox proportional hazard ratios by treatment group for time to first post-baseline PAD event are shown in Figure 2 . Following adjustment for baseline characteristics, participants assigned to amlodipine and lisinopril showed similar risks compared with those assigned to chlorthalidone (HR, 0.86; 95 % CI, 0.72-1.03, and HR, 0.98; 95 % CI, 0.83-1.17, respectively) for first clinically advanced PAD event. Similarly, there was no difference in post-PAD mortality in either comparison (Table 2) . When looking at pre-specified subgroups plus the (post-hoc) history of coronary heart disease subgroup for those with in-trial PAD, there were no significant subgroup-treatment interactions between amlodipine and chlorthalidone or lisinopril and chlorthalidone (Fig. 3) .
In-trial pre-and post-PAD nonfatal events and post-PAD total and cause-specific mortality are provided in Table 3 . Both preceding and following PAD events, there were no differences in incident myocardial infarctions, strokes, heart failure, or coronary revascularization procedures in either the amlodipine vs. chlorthalidone or lisinopril vs. chlorthalidone comparisons. Similarly, total mortality among those with PAD did not differ in either comparison. There were also no treatment group differences regarding cause-specific mortality. Overall mortality rates at 1, 5, and 10 years post-PAD were 9.6, 41.9, and 69.8 %, respectively (Fig. 4) .
DISCUSSION
The final results of the randomized phase of ALLHAT, published in 2002, 16 showed no significant difference in the prespecified PAD endpoint (treated medically as an outpatient, hospitalized, or revascularized PAD) between those assigned to amlodipine compared to their counterparts in the chlorthalidone group (though there was a trend toward less PAD in the amlodipine group: HR, 0.87; 95 % CI, 0.75-1.01) nor between lisinopril and chlorthalidone (HR, 1.04; 95 % CI, 0.90-1.19). 16 In the current analysis, using a more rigorous endpoint of documented new or recurrent PAD hospitalization or revascularization, i.e., clinically advanced PAD, than previously used, we again show no difference in risk of treatment with The choice of antihypertensive therapy must reflect the best scientific evidence and take into account all known benefits and risks of the antihypertensive drugs. Toward that end, active-controlled comparative trials are required. Optimal antihypertensive treatment to prevent new onset or recurrent PAD remains undetermined, especially given the need to take into account all outcomes associated with a given treatment. Evidence regarding use of beta-blockers in hypertensive patients with PAD is limited; active-controlled clinical trials have yet to prove their superiority.
Questions not yet fully addressed have arisen regarding possible compromised blood flow to the extremities while on betablockers. Though non-selective beta-blockers have traditionally been contraindicated in patients with PAD, newer betablockers such as the non-selective beta blocker carvedilol and the β 1 -selective nebivolol, both of which have vasodilating effects, have shown promise. 23, 24 The International Verapamil-SR/Tradandolapril Study (INVEST), in a post-hoc analysis of hypertensive participants with coronary heart disease and concomitant PAD, reported no significant difference in primary outcome (all-cause death, non-fatal stroke, or nonfatal myocardial infarction) between participants assigned to a Abbreviations: A amlodipine; BMI body mass index; C chlorthalidone; CABG coronary artery bypass graft; CHD coronary heart disease; eGFR calcium antagonist-based treatment strategy when compared with those assigned to a beta-blocker-based strategy. 25 The potential vasoprotective effects of ACE-inhibitors on systemic vasculature, including inhibition of multiple steps in atherogenesis, have been described. 26, 27 Placebo-controlled trials have reported benefits of the ACE-inhibitor ramipril over placebo in reducing clinical outcomes in persons with clinical and subclinical PAD, 28, 29 but conclusive comparative effectiveness clinical trial data are lacking. 30 Practice guidelines for treatment of at-risk hypertensive patients with PAD suggest using ACE-inhibitors and/or beta-blockers, but are based largely on placebo-controlled trials. 31 A definitive case has not been convincingly made for using any of these antihypertensive classes-calcium channel blockers, ACE-inhibitors, or beta-blockers-in hypertensive patients at risk of developing PAD.
Several limitations must be considered in interpreting this report. First, history of PAD at baseline was not specifically collected; thus, the actual PAD incidence cannot be determined. However, randomization presumably allowed for equitable distribution across treatment groups of participants with and without pre-enrollment PAD. Formal screening for PAD at follow-up visits was not performed; thus, asymptomatic PAD was likely missed. In addition, post-trial morbidity, medication data, and laboratory values were not available for analyses; thus, possible links between the PAD events described here and post-trial mortality may have been missed. Definitions and diagnostic criteria for PAD differ among studies, complicating comparisons between different reports. Gregg and colleagues, using NHANES data, defined PAD according to precise ankle-brachial index results obtained under protocol-specific guidelines; 32 ALLHAT defined the PAD outcome based on symptomatic disease requiring presentation to the physician or hospital and/or the performance of lower extremity arterial revascularization procedures or amputations. In an attempt to establish a more rigorous definition, we limited PAD in this study to lower extremity disease that could be verified: those events requiring hospitalization or revascularization, both of which provided hospital or operative documentation for central review (albeit further decreasing the sample size somewhat with exclusion of non-hospitalized, non-revascularized subjects). Indeed, the small sample size, and the resultant lack of power, may at least partially contribute to the absence of significant interactions in multiple subgroup analyses that were performed to assess the impact of three antihypertensive treatments on new PAD events. As in other trials, secondary outcomes including PAD were not presented to an adjudications committee for diagnostic validation, though the physician-led central review of documentation established a level of confidence in the *Adjusted for baseline variables of age, race, ethnicity, gender, heart rate, pulse pressure, aspirin use, history of atherosclerotic cardiovascular disease, history of coronary heart disease, history of diabetes, current smoking, ever smoking, BMI, and estimated glomerular filtration rate validity of events. In addition, the large sample size and randomized, double-blind design of ALLHAT provides reassurance of equity in event reporting across the study treatment groups. 19 Further, early and fortuitous planning of post-trial follow-up of ALLHAT participants provided outcome data by which we could assess long-term sequelae of intrial events among participants who experienced in-trial PAD. 17, 33 PAD is a marker for high cardiovascular risk, including risk of mortality. 34, 35 In these analyses PAD is associated with high post-event mortality: 70 % over 10 years of follow-up. Reduction of major modifiable risk factors, including hypertension, is critical, but the optimal antihypertensive therapy, when considering multiple cardiovascular disease outcomes, remains undetermined. 6 ALLHAT data provide several lessons. First, once PAD, sufficiently advanced as to require hospitalization or revascularization, develops, it is associated with a high rate of subsequent cardiovascular disease morbidity and all-cause mortality regardless of the type of antihypertensive treatment, thus underscoring the need for cardiovascular disease prevention. Second, decisions as to choice of antihypertensive treatment in high-risk hypertensive patients at risk of PAD must consider all evidence of clinical outcomes associated with that treatment. Our findings here do not dispute previously reported ALLHAT findings that neither the calcium-channel blocker amlodipine nor the ACE-inhibitor lisinopril is superior to the diuretic chlorthalidone in preventing coronary heart disease or other major cardiovascular outcomes. Rather, they reinforce the compelling need for comparative clinical outcome trials similar to ALLHAT to assess optimal drug combinations and to address optimal prevention of PAD in the context of other major cardiovascular events. 
